<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00231283</url>
  </required_header>
  <id_info>
    <org_study_id>P04-6324</org_study_id>
    <nct_id>NCT00231283</nct_id>
  </id_info>
  <brief_title>NEXUS Study for the Treatment of de Novo Native Coronary Artery Lesions</brief_title>
  <official_title>A Multicenter, Non-Randomized Study of the CYPHER NxT Sirolimus-Eluting Coronary Stent on BX SONIC OVER-THE-WIRE (OTW) Stent Delivery System(SDS)for the Treatment of de Novo Native Coronary Artery Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cordis Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cordis Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the effectiveness and safety of the CYPHER NxT
      Sirolimus-eluting Coronary Stent on the BX SONIC Over-the-Wire (OTW) Stent Delivery System
      (SDS) in patients with de novo native coronary artery lesions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">July 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Achieved Procedure Success From Post-procedure to Hospital Discharge</measure>
    <time_frame>From post-procedure up to hospital discharge</time_frame>
    <description>Procedure Success is defined as the final residual diameter stenosis &lt; 50 percent by Quantitative Coronary Angiography (QCA) using any percutaneous method, without the occurrence of death, Myocardial Infarction (MI), or repeat revascularization of the target lesion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experienced Any Major Adverse Cardiac Events From Post-procedure to 30 Days Later</measure>
    <time_frame>From post-procedure up to 30 days</time_frame>
    <description>Major Adverse Cardiac Events (MACE) consists of death, Myocardial Infarction (Q-wave and Non Q-wave), emergent Coronary Artery Bypass Graft (CABG) or Target Lesion Revascularization (TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experienced Any Major Adverse Cardiac Events From Post-procedure to Hospital Discharge</measure>
    <time_frame>From post-procedure up to hospital discharge</time_frame>
    <description>Major Adverse Cardiac Events (MACE) consists of death, Myocardial Infarction (Q-wave and Non Q-wave), emergent Coronary Artery Bypass Graft (CABG) or Target Lesion Revascularization (TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experienced Any Major Adverse Cardiac Events From Post-procedure to 12 Months Later</measure>
    <time_frame>From post-procedure up to 12 months</time_frame>
    <description>Major Adverse Cardiac Events (MACE) consists of death, Myocardial Infarction (Q-wave and Non Q-wave), emergent Coronary Artery Bypass Graft (CABG) or Target Lesion Revascularization (TLR).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CYPHER NxT Sirolimus-eluting Coronary Stent on the BX SONIC Over-the-wire Stent Delivery System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CYPHER NxT SES ON BX SONIC OTW STENT DELIVERY SYSTEM (SDS)</intervention_name>
    <description>CYPHER NxT Sirolimus-eluting Coronary Stent on the BX SONIC Over-the-wire Stent Delivery System</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or non-pregnant female patients 18 years of age

          2. Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society
             Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald
             Classification B&amp;C, I-II) OR patients with documented silent ischemia;

          3. Treatment of a single de novo target lesion in a major native coronary artery;

          4. Target lesion is 2.5 mm and 3.5 mm in diameter (visual estimate);

          5. Target lesion is 30mm in length (visual estimate);

          6. Target lesion stenosis is &gt; 50% and &lt; 100% (visual estimate);

        Exclusion Criteria:

          1. Patient has experienced a Q-wave or non-Q-wave myocardial infarction with documented
             total CK &gt; 2 times normal within the preceding 24 hours and the CK and CK-MB enzymes
             remain above normal at the time of treatment;

          2. Has unstable angina classified as Braunwald III B or C, or is having a peri-infarction
             angina;

          3. Significant (&gt; 50%) stenoses proximal or distal to the target lesion that might
             require revascularization or impede runoff;

          4. Documented Left ventricular ejection fraction 25%;

          5. Totally occluded vessel (TIMI 0 level);

          6. Impaired renal function (creatinine &gt; 3.0 mg/dl) at the time of treatment;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emerson Perin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Heart Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Heart Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2005</study_first_submitted>
  <study_first_submitted_qc>September 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2005</study_first_posted>
  <results_first_submitted>November 18, 2008</results_first_submitted>
  <results_first_submitted_qc>March 11, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 23, 2010</results_first_posted>
  <last_update_submitted>April 13, 2010</last_update_submitted>
  <last_update_submitted_qc>April 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2010</last_update_posted>
  <responsible_party>
    <name_title>Sidney Cohen, MD, PhD, Vice President</name_title>
    <organization>Cordis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First patient enrolled was Apr 2004 and last patient enrolled was Jul 2004.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>CYPHER NxT Stent on the BX SONIC OTW SDS</title>
          <description>CYPHER NxT Sirolimus-eluting Coronary Stent on the BX SONIC Over-the-wire Stent Delivery System</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CYPHER NxT Stent on the BX SONIC OTW SDS</title>
          <description>CYPHER NxT Sirolimus-eluting Coronary Stent on the BX SONIC Over-the-wire Stent Delivery System</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.39" spread="10.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patients with Diabetes Mellitus</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>With Diabetes Mellitus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without Diabetes Mellitus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Achieved Procedure Success From Post-procedure to Hospital Discharge</title>
        <description>Procedure Success is defined as the final residual diameter stenosis &lt; 50 percent by Quantitative Coronary Angiography (QCA) using any percutaneous method, without the occurrence of death, Myocardial Infarction (MI), or repeat revascularization of the target lesion</description>
        <time_frame>From post-procedure up to hospital discharge</time_frame>
        <population>Patients who were followed up to hospital discharge</population>
        <group_list>
          <group group_id="O1">
            <title>CYPHER NxT Stent on the BX SONIC OTW SDS</title>
            <description>CYPHER NxT Sirolimus-eluting Coronary Stent on the BX SONIC Over-the-wire Stent Delivery System</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved Procedure Success From Post-procedure to Hospital Discharge</title>
          <description>Procedure Success is defined as the final residual diameter stenosis &lt; 50 percent by Quantitative Coronary Angiography (QCA) using any percutaneous method, without the occurrence of death, Myocardial Infarction (MI), or repeat revascularization of the target lesion</description>
          <population>Patients who were followed up to hospital discharge</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of participants</param_type>
            <param_value>97.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.71</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>91.5</ci_lower_limit>
            <ci_upper_limit>99.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Experienced Any Major Adverse Cardiac Events From Post-procedure to 30 Days Later</title>
        <description>Major Adverse Cardiac Events (MACE) consists of death, Myocardial Infarction (Q-wave and Non Q-wave), emergent Coronary Artery Bypass Graft (CABG) or Target Lesion Revascularization (TLR).</description>
        <time_frame>From post-procedure up to 30 days</time_frame>
        <population>Patients who had 30 days clinical follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>CYPHER NxT Stent on the BX SONIC OTW SDS</title>
            <description>CYPHER NxT Sirolimus-eluting Coronary Stent on the BX SONIC Over-the-wire Stent Delivery System</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced Any Major Adverse Cardiac Events From Post-procedure to 30 Days Later</title>
          <description>Major Adverse Cardiac Events (MACE) consists of death, Myocardial Infarction (Q-wave and Non Q-wave), emergent Coronary Artery Bypass Graft (CABG) or Target Lesion Revascularization (TLR).</description>
          <population>Patients who had 30 days clinical follow-up.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of participants</param_type>
            <param_value>3.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.6</ci_lower_limit>
            <ci_upper_limit>8.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Experienced Any Major Adverse Cardiac Events From Post-procedure to Hospital Discharge</title>
        <description>Major Adverse Cardiac Events (MACE) consists of death, Myocardial Infarction (Q-wave and Non Q-wave), emergent Coronary Artery Bypass Graft (CABG) or Target Lesion Revascularization (TLR).</description>
        <time_frame>From post-procedure up to hospital discharge</time_frame>
        <population>Patients who were followed up to hospital discharge</population>
        <group_list>
          <group group_id="O1">
            <title>CYPHER NxT Stent on the BX SONIC OTW SDS</title>
            <description>CYPHER NxT Sirolimus-eluting Coronary Stent on the BX SONIC Over-the-wire Stent Delivery System</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced Any Major Adverse Cardiac Events From Post-procedure to Hospital Discharge</title>
          <description>Major Adverse Cardiac Events (MACE) consists of death, Myocardial Infarction (Q-wave and Non Q-wave), emergent Coronary Artery Bypass Graft (CABG) or Target Lesion Revascularization (TLR).</description>
          <population>Patients who were followed up to hospital discharge</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of participants</param_type>
            <param_value>3.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.6</ci_lower_limit>
            <ci_upper_limit>8.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Experienced Any Major Adverse Cardiac Events From Post-procedure to 12 Months Later</title>
        <description>Major Adverse Cardiac Events (MACE) consists of death, Myocardial Infarction (Q-wave and Non Q-wave), emergent Coronary Artery Bypass Graft (CABG) or Target Lesion Revascularization (TLR).</description>
        <time_frame>From post-procedure up to 12 months</time_frame>
        <population>Patients who had at least 330 days clinical follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>CYPHER NxT Stent on the BX SONIC OTW SDS</title>
            <description>CYPHER NxT Sirolimus-eluting Coronary Stent on the BX SONIC Over-the-wire Stent Delivery System</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced Any Major Adverse Cardiac Events From Post-procedure to 12 Months Later</title>
          <description>Major Adverse Cardiac Events (MACE) consists of death, Myocardial Infarction (Q-wave and Non Q-wave), emergent Coronary Artery Bypass Graft (CABG) or Target Lesion Revascularization (TLR).</description>
          <population>Patients who had at least 330 days clinical follow-up.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of participants</param_type>
            <param_value>10.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>5.1</ci_lower_limit>
            <ci_upper_limit>18.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>CYPHER NxT Stent on the BX SONIC OTW SDS</title>
          <description>CYPHER NxT Sirolimus-eluting Coronary Stent on the BX SONIC Over-the-wire Stent Delivery System</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>The number at risk is defined as the number of patients who had sufficient (one year) follow-up or who had an event prior to the end of follow-up.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial Infarction (Q wave or Non-Q wave)</sub_title>
                <description>The number at risk is defined as the number of patients who had sufficient one year post-procedure follow-up or who had at least one event prior to the end of follow-up.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Emergent CABG</sub_title>
                <description>The number at risk is defined as the number of patients who had sufficient one year post-procedure follow-up or who had at least one event prior to the end of follow-up.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Target Lesion Revascularization</sub_title>
                <description>The number at risk is defined as the number of patients who had sufficient one year post-procedure follow-up or who had at least one event prior to the end of follow-up.</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Target Vessel Revascularization not involving the Target Lesion</sub_title>
                <description>The number at risk is defined as the number of patients who had sufficient one year post-procedure follow-up or who had at least one event prior to the end of follow-up.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Target Vessel Revascularization</sub_title>
                <description>The number at risk is defined as the number of patients who had sufficient one year post-procedure follow-up or who had at least one event prior to the end of follow-up.</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Target Vessel Failure</sub_title>
                <description>The number at risk is defined as the number of patients who had sufficient one year post-procedure follow-up or who had at least one event prior to the end of follow-up.</description>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Major Vascular Complications</sub_title>
                <description>The number at risk is defined as the number of patients who had sufficient one year post-procedure follow-up or who had at least one event prior to the end of follow-up.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Ischemic Complications</sub_title>
                <description>The number at risk is defined as the number of patients who had sufficient one year post-procedure follow-up or who had at least one event prior to the end of follow-up.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sidney Cohen, MD PhD, Vice President</name_or_title>
      <organization>Cordis</organization>
      <phone>650 614-2726</phone>
      <email>scohen7@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

